INCY News and Press, Incyte Corporation From 11/02/22

Summary Incyte reported 20% y/y product revenue growth in Q3 2022. Opzelura revenue grew $38 million y/y. Opzelura revenue is likely to grow quickly in Q4 and in 2023. Incyte ( INCY ) is a large-cap pharmaceutical company known mainly for Jakafi, a JAK inhibitor ...

Summary CTI BioPharma Corp. will be reporting third quarter financial results after the market closes on Monday, November 7, 2022. Analysts predict Q3 revenues of $17.17 million, all from sales of CTI BioPharma's lone commercial product. VONJO is likely to take advantage of th...

Incyte ( NASDAQ: INCY ) is trading ~5% higher after the company raised 2022 Jakafi net product revenues. The company tightened its full year 2022 guidance of chronic GVHD treatment Jakafi net product revenues to be $2.38B - $2.40B from prior outlook of $2...

The following slide deck was published by Incyte Corporation in conjunction with their 2022 Q3 earnings call. For further details see: Incyte Corporation 2022 Q3 - Results - Earnings Call Presentation

Incyte Corporation (INCY) Q3 2022 Earnings Conference Call November 1, 2022 08:00 ET Company Participants Christine Chiou - Head, Investor Relations Hervé Hoppenot - Chairman, President and Chief Executive Officer Barry Flannelly - Executive Vice President a...

Incyte press release ( NASDAQ: INCY ): Q3 Non-GAAP EPS of $0.60 misses by $0.10 . Revenue of $823.03M (+1.2% Y/Y) misses by $20.62M . Total net product revenues grew to $713 million (+20% Y/Y) as a result of strong Jakafi ® (ruxolitinib) and Opzelura...

– Total net product revenues grew to $713 million (+20% Y/Y) as a result of strong Jakafi ® (ruxolitinib) and Opzelura ™ (ruxolitinib) cream net product revenues – Jakafi net product revenues of $620 million in Q3’22 (+13% Y/Y); raising...

Summary After a barely discernible bottoming process, the rally has become obvious. I got a lot of blowback for taking this position but here we are. The market has fallen so much that it has run out of sellers. There are fundamental reasons why the market can rally here. Will...

Data served as basis for recent FDA approval of ruxolitinib cream (Opzelura™) 1.5% for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older Fifty-two week data from the Phase 3 TRuE-V clinical trial program demonstrate...

Summary ARK Invest’s 13F portfolio value decreased from $16.91B to $14.35B this quarter. UiPath, Ginkgo Bioworks, and NVIDIA were increased while decreasing Spotify, Ionis Pharma, CRISPR Therapeutics, and Coinbase Global. The top three positions are Tesla Inc., Zoom Vid...